Citron Research says it has a 'smoking gun' on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Valeant Pharma (VRX) Shares Active Ahead of Monday's Conference Call
October 23, 2015 3:53 PM EDTEmbattled specialty pharmaceutical company Valeant Pharma (NYSE: VRX) was in focus heading into the close of trading Friday, as it gets set to address investors during a critical conference call on Monday morning. On the call, management must untangle its relationship with... More
Valeant Pharma (VRX) Used Backdoor Approach to Gain Pharmacy Stake in California - ProPublica
October 22, 2015 5:48 PM EDTValeant Pharma (NYSE: VRX) is on watch following a new article from ProPublica which highlights documents that raise new questions about the company's pharmacy relationships in California.
From the... More
Deutsche Bank 'Remains Cautious' on Valeant (VRX); Analyst Maintains Hold Rating
October 22, 2015 9:37 AM EDTDeutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $204. Analyst Gregg Gilbert said he remains cautious on the stock given uncertainties related to the drug pricing, its specialty pharmacy distribution model, and related government inquiries.
Gilbert explained, "VRX shares have been under significant pressure, most recently following allegations related to its specialty pharmacy distribution model. While it is difficult to predict how more conservative pricing behavior and other potential changes could affect revenue growth, we thought it would be helpful to look at... More
Valeant Pharma (VRX) Taps Lows Below $90/Share
October 21, 2015 1:24 PM EDTValeant Pharma (NYSE: VRX) declined 38% to session lows at around 1:20 pm on Tuesday, briefly traded under $90 per share. The massive slide follows Citron Research's fraud report earlier. So far the company hasn't responded, which might be viewed as a negative by some investors.
... MoreIcahn Wishes He Was Short Valeant (VRX) Stock - CNBC
October 21, 2015 12:42 PM EDTCarl Icahn said Valeant Pharma (NYSE: VRX) is 'prime example' of inversion, according to an interview on CNBC today. Icahn also noted that he doesn't have a long position in the stock, but wishes he had a short position.
... MoreMizuho Weighs in on Panic in Specialty Pharmaceuticals Sector (VRX) (AGN) (ENDP) (SCMP) (JAZZ) (MNK)
October 21, 2015 12:39 PM EDTMizuho Securities analyst Irina Koffler offered some comments on the specialty pharmaceutical sector give the panic following reports of fraud at Valeant Pharma (NYSE: VRX).
Koffler key points are highlighted below:
Our Neutral thesis on VRX is intact: We cannot verify or dispute the allegations made by Citron Research or SIRF about Valeant's Philidor pharmacy. That said, it almost doesn't matter as the stock appears broken and management will now have to defend the story rather than focus on its organic growth and M&A. We initially used a 14% WACC... More